Smart Drug Delivery System for Dual Nuclear Medical Cytotoxic Theranostics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using cytotoxic pharmaceuticals often cause severe side effects due to their non-targeted administration, and nuclear-medical diagnostics and theranostics require complex and inefficient methods for tumor-specific radioisotope delivery, which can be harmful to healthy tissues.
Innovation Solution
A smart drug delivery system comprising compounds with a chelator for radioisotope complexation, a cytotoxic compound, and a biological targeting vector, linked by specific spacers and linkers, allowing for targeted dual nuclear-medical and cytotoxic theranostics, enabling both diagnostic and therapeutic modalities with high affinity and selectivity for tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional systemic chemotherapy is used with high doses of cytotoxic pharmaceuticals, then cancer cells are effectively targeted, but healthy tissue is damaged causing severe side effects
Solution Approach 1:
The pharmaceutical compound is segmented into distinct functional modules: a cytotoxic agent (CT), a targeting vector (TV), and a chelator (Chel) for radioisotope complexation. This segmentation allows the cytotoxic component to be separated from non-targeted distribution, while the targeting vector directs the compound specifically to tumor cells overexpressing membrane-bound proteins, thereby improving cancer cell killing efficiency while reducing damage to healthy tissue
Solution Approach 2:
A targeting vector (TV) acts as an intermediary between the cytotoxic agent and tumor cells. The TV comprises components that bind specifically to membrane-bound proteins significantly overexpressed on tumor cell envelopes, mediating the selective delivery of the cytotoxic compound to cancer cells while sparing healthy cells with normal protein expression levels
2Object-affected harmful factors
If low-dose targeted cytotoxic pharmaceuticals are used with targeting vectors, then side effects are reduced, but treatment efficacy may be compromised
Solution Approach 1:
The invention merges multiple therapeutic modalities into a single compound: cytotoxic chemotherapy, nuclear-medical theranostics, and targeted delivery. The compound combines a cytotoxic agent with a radioisotope-chelator complex and targeting vector, enabling both diagnostic imaging and therapeutic action at low doses, thereby maintaining treatment efficacy while reducing side effects through the synergistic effect of multiple mechanisms
Solution Approach 2:
The pharmaceutical compound is designed with multi-functionality, serving as both a cytotoxic agent and a theranostic probe. The chelator component enables complexation with radioisotopes for nuclear-medical imaging and therapy, while the targeting vector provides selective tumor cell binding, making the single compound capable of diagnosis, therapy, and targeted delivery simultaneously
3Measurement precision
If nuclear-medical labeling precursors are used for tumor-specific radioisotope delivery, then diagnostic accuracy is improved, but complex synthesis and trial-and-error optimization are required
Solution Approach 1:
The same multi-functional compound structure is used for both diagnostic imaging and therapeutic applications. The compound comprises a universal scaffold that can be labeled with different radioisotopes depending on the intended use (diagnostic or therapeutic), eliminating the need for separate synthesis pathways for different applications and reducing overall synthesis complexity
Solution Approach 2:
The chelator and targeting vector are pre-assembled into a stable conjugate structure before radioisotope labeling. This preliminary assembly creates a ready-to-label precursor that requires only simple radioisotope complexation, avoiding complex synthesis steps and enabling rapid preparation of radiolabeled compounds for both diagnostic and therapeutic purposes
4Object-affected harmful factors
If radioisotopes with short half-life are used in diagnostic examinations, then radiation dose to healthy tissue is minimized, but the time window for effective treatment is limited
Solution Approach 1:
The invention provides dynamic adaptability by using the same compound scaffold with different radioisotopes selected based on the required time window. For diagnostic imaging, short half-life isotopes are used to minimize radiation exposure, while for therapeutic applications, longer half-life isotopes can be employed to extend the treatment duration, allowing optimization of both radiation safety and treatment efficacy for different clinical scenarios
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables targeted cancer treatment with reduced side effects by ensuring high tumor specificity and efficient delivery of both diagnostic and therapeutic agents, predicting patient response and optimizing treatment suitability based on pharmacokinetic and pharmacodynamic properties.
Implementation Method 1
Chel is a radical of a chelator for the complexation of a radioisotope
Data Source
AI summary
The invention generally relates to a smart drug delivery system for dual nuclear medical cytotoxic theranostics incorporating either (i) a first compound with the structure CT-L1-Chel-S1-TV oror (ii) a second compound with the structure Chel-S-TV and a third compound with the structure CT-L-TV. In the first, second and third compounds Chel is a radical of a chelating agent for complexing a radioisotope; CT is a radical of a cytotoxic compound; TV is a biological targeting vector; L1 and L are each linkers; S1, S2 and S are each spacers.